GlassScriptPhysician profile
Anthony P Merrill
NPI 1730399304
$17,323.51
in general payments reported to CMS, 2019-2025
46 companies · $4,126 in 2025
The $4,126 reported for 2025 was more than what 90% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,458 · 2020: $486 · 2021: $197 · 2022: $2,099 · 2023: $4,213 · 2024: $3,743 · 2025: $4,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,885.57 |
| Education | $197.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,960.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,493.56 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,291.95 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,187.92 | 2019-2025 | Tremfya, Stelara, Simponi |
| Madrigal Pharmaceuticals | $1,061.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $1,006.77 | 2019-2025 | |
| Genzyme Corporation | $928.07 | 2022-2025 | |
| Qol Medical, LLC | $712.37 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $654.96 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $576.31 | 2022-2025 | Dupixent |
| Celgene Corporation | $377.51 | 2022-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $373.89 | 2019-2024 | Linzess |
| Lilly USA, LLC | $331.45 | 2023-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $248.65 | 2023-2025 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $240.75 | 2023-2025 | Iqirvo, Bylvay |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $235.43 | 2019-2025 | Ocaliva |
| Celltrion USA INC. | $213.97 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
| Ardelyx, INC. | $213.51 | 2022-2025 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $208.65 | 2023 | Amvuttra, Givlaari |
| Nestle Healthcare Nutrition INC. | $204.50 | 2022-2023 | |
| Fresenius Kabi USA, LLC | $196.00 | 2023-2024 | Idacio |
| Ferring Pharmaceuticals INC. | $185.90 | 2022-2023 | Rebyota |
| Echosens North America, INC. | $185.40 | 2023 | Fibroscan |
| E.R. Squibb & Sons, L.L.C. | $151.67 | 2022-2023 | Zeposia |
| Lucid Diagnostics INC. | $134.37 | 2021-2024 | |
| Aimmune Therapeutics, INC. | $128.68 | 2024-2025 | Vowst |
| Merck Sharp & Dohme LLC | $120.72 | 2022-2024 | Dificid |
| Dova Pharmaceuticals | $119.83 | 2019 | |
| Olympus America INC. | $66.82 | 2023-2025 | Single Use Repositionable Clip, Endoclot Phs, Visiglide |
| Daiichi Sankyo INC. | $54.00 | 2019-2023 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.99 | 2023-2024 | Cyltezo |
| W. L. Gore & Associates, INC. | $51.40 | 2022-2023 | Gore Cardioform Septal Occluder |
| Redhill Biopharma INC. | $51.23 | 2020-2022 | |
| Braintree Laboratories, INC. | $44.64 | 2022-2023 | Sutab, Suflave |
| Shionogi INC | $39.94 | 2019 | |
| Organon LLC | $29.03 | 2024 | |
| Fujifilm Healthcare Americas Corporation | $28.48 | 2024 | Fujifilm |
| Orphalan INC | $27.33 | 2025 | Cuvrior |
| Biocon Biologics INC | $21.33 | 2025 | Yesintek |
| Medtronic, INC. | $18.89 | 2021 | |
| Acadia Pharmaceuticals INC | $17.94 | 2025 | Daybue |
| Teva Pharmaceuticals USA, INC. | $17.64 | 2024 | Simlandi |
| Evoke Pharma, INC. | $17.51 | 2025 | |
| Medtronic USA, INC. | $15.57 | 2019 | |
| Allergan, INC. | $14.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $9.24 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Merrill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.